Biren Technology is placing 153 million new H shares at HK$46.20 per share, representing a discount of approximately 9.94% to the last closing price. The gross proceeds are approximately HK$7.069 billion with net proceeds of approximately HK$7.038 billion. The placement is conducted under the general mandate without requiring shareholder approval. Net proceeds will be allocated with approximately 20% for cutting-edge R&D, 60% for next-gen product commercialization and production, 10% for strategic investments and acquisitions, and 10% for working capital and general corporate purposes. The company has also agreed to a 90-day lock-up undertaking post-closing.
Xunce Technology signed a strategic cooperation MOU with GTEC to extend its data tokenization capabilities into industrial smart manufacturing. The parties will cooperate on industrial data standardization, industrial intelligent agents, and industrial digitalization, jointly exploring the AI data infrastructure Token factory model and Token billing business models for industrial data assetization, and launching the "Token Factory Alliance" ecosystem. Specific cooperation arrangements will be formalized in subsequent contracts.
Gushengtang's subsidiary Beijing Gushengtang Health Management plans to acquire controlling stakes in Shahe Hospital and Beijing Hongyang Hospital, which will become wholly-owned subsidiaries and be consolidated upon completion. The acquisitions aim to expand the offline medical network in Beijing and create synergies, funded by placement proceeds, convertible bond issuance, and idle funds. The transactions do not constitute connected or notifiable transactions.
By the close of trading on Jul 3, 2026, ALEBUND-B(09637.HK) saw a gain of 18.75% in its share price, closing at HKD 30.28. During the session, it reached an intraday high of HKD 31.04 and touched an intraday low of HKD 26.02.
By the close of trading on Jul 3, 2026, WENGE AI(01956.HK) saw a gain of 15.9% in its share price, closing at HKD 88.95. During the session, it reached an intraday high of HKD 91.95 and touched an intraday low of HKD 71.55.
TENCENT(00700.HK) will spend HKD 500.89 million to repurchase 1.15 million shares on Jul 3, 2026 .
NewTimeSpace News: Northeast Electric Development Company Limited (00042.HK) announced that it received an enforcement notice from Heping District People’s Court of Shenyang City on 3 July 2026 in relation to a dispute over an assignment of creditor’s rights contract between Liaoning Trust and Investment Corporation and the Company. The Company is required to immediately perform its obligations under the judgment upon receipt of the notice, failing which compulsory enforcement will be initiated. A provision of approximately RMB63.97 million has been recognised in the Company’s 2025 annual financial statements for this case.
NewTimeSpace News: EDICO Holdings Limited (08450.HK) announced that the Group has set up a new business division principally engaged in trading card game and sports card businesses, operated through its non-wholly-owned subsidiary Hong Kong Trading Card Game Limited (HKTCG). Its flagship store covering 21,000 square feet at iSQUARE, Tsim Sha Tsui will officially open on 4 July 2026.
NewTimeSpace News: By the close of trading on Jul 3, 2026, LAIFUAL(03952.HK) saw a gain of 44.95% in its share price, closing at HKD 94. During the session, it reached an intraday high of HKD 100 and touched an intraday low of HKD 62.55.
NewTimeSpace News: China Agri-Products Exchange announced on July 3 that the Company has issued Series 6 Tranche 1 notes under its HK$1,000,000,000 medium term note programme with a principal amount of HK$22 million and an effective interest rate ranging from approximately 1.9% to 5.4%.
NewTimeSpace News: New Century Healthcare Holding Co. Limited (01518.HK) issued an announcement stating that Chengdu New Century Women & Children’s Hospital, a non-wholly-owned subsidiary, faces severe headwinds arising from falling birth rates and fierce market competition. The hospital registered an annual loss of approximately RMB45.9 million in 2025 and has never generated any operating profit since its acquisition in 2018. The Company is negotiating rent relief with the landlord and urging management to roll out additional initiatives to boost profitability.
NewTimeSpace News: China New Town Development Company Limited (01278.HK) announced that as at 30 June 2026, the Group’s total fixed-income project investment portfolio net of impairment provisions for risky projects stood at approximately RMB3.053 billion. Two new projects in Wuxing of Huzhou and Yandu of Yancheng were added in the second quarter, while four projects in Wuxi, Liyang and Yancheng were divested, bringing aggregate principal recoveries to RMB1.1 billion.
NewTimeSpace News: Zai Lab announced on July 3 that the Company has granted share options and restricted share units under its 2024 Equity Incentive Plan. Among the awards, 80,393 restricted share units were granted to Dr. Samantha Du, Chairperson and Chief Executive Officer, with approval obtained from the independent non-executive directors.
NewTimeSpace News: Allan International Holdings Ltd. (00684.HK) issued an announcement disclosing that as at the date of the announcement, the Company’s public float is 24.04%, which remains below the minimum 25% requirement stipulated under the Listing Rules. The Board is considering adopting a share scheme and continuing discussions with key shareholders and core connected persons, and expects to finalise a detailed restoration plan by the end of the third quarter of 2026.
NewTimeSpace News: Nanjing Panda Electronics announced on July 3 that the Company subscribed to a structured deposit product issued by Huaxia Bank with a principal amount of RMB 50 million on July 2. Together with three tranches subscribed in April previously, the total principal of Huaxia Bank structured deposit products held by the Company has reached RMB 300 million.
NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced on 3 July that the New Drug Application (NDA) for its Class 2.2 new drug ropivacaine hydrochloride sustained-release solution has been accepted, which is developed for long-acting postoperative analgesia. As the world’s first long-acting ropivacaine preparation administered via wound coating, it can deliver sustained analgesia for up to 72 hours. Phase III clinical trials demonstrated superior efficacy versus control agents with favourable overall safety profiles.
